Table 3 Correlation between NPM2 expression level (negative vs. low expression vs. high expression) and clinicopathological characteristics of MPM
Variable | n (%) | NPM2 expression level (n, %) | P | ||
|---|---|---|---|---|---|
Negative | Low | High | |||
Gender | 0.501 | ||||
Male | 47 (48.9) | 38 (41.3) | 5 (5.4) | 4 (5.6) | |
Female | 45 (51.1) | 32 (34.8) | 6 (6.5) | 7 (7.6) | |
Age | 0.723 | ||||
< 65 | 75 (81.5) | 58 (63.0) | 8 (8.7) | 9 (9.8) | |
≥ 65 | 17 (18.5) | 12 (13.0) | 3 (3.3) | 2 (2.2) | |
History of targeted therapy | 0.173 | ||||
No | 65 (70.7) | 52 (56.5) | 5 (5.4) | 8 (8.7) | |
Yes | 27 (29.3) | 18 (19.6) | 6 (6.5) | 3 (3.3) | |
Increased preoperative TMsa | 0.139 | ||||
No | 28 (30.4) | 18 (19.6) | 4 (4.3) | 6 (6.5) | |
Yes | 64 (69.6) | 52 (56.5) | 7 (7.6) | 5 (5.4) | |
Ascites (mL) | |||||
0 | 19 (20.7) | 12 (13.0) | 2 (2.2) | 5 (5.4) | 0.256 |
0–1000 | 16 (17.4) | 11 (12.0) | 3 (3.3) | 2 (2.2) | |
> 1000 | 57 (62.0) | 47 (51.1) | 6 (6.5) | 4 (4.3) | |
PCI score | 0.094 | ||||
< 20 | 26 (28.3) | 16 (17.4) | 4 (4.3) | 6 (6.5) | |
≥ 20 | 66 (71.7) | 54 (58.7) | 7 (7.6) | 5 (5.4) | |
CC score | 0.020 | ||||
0/1 | 48 (52.2) | 32 (34.8) | 6 (6.5) | 10 (10.9) | |
2/3 | 44 (47.8) | 38 (41.3) | 5 (5.4) | 1 (1.1) | |
Ki-67 index | 0.093 | ||||
≤ 9% | 15 (16.3) | 8 (8.7) | 4 (4.3) | 3 (20.0) | |
> 9% | 77 (83.7) | 62 (67.4) | 7 (7.6) | 8 (8.7) | |
Vascular tumor emboli | 0.004 | ||||
No | 67 (72.8) | 46 (50.0) | 10 (10.9) | 11 (12.0) | |
Yes | 25 (27.2) | 24 (26.1) | 1 (1.1) | 0 (0.0) | |
SAEs | 0.009 | ||||
No | 63 (68.5) | 44 (47.8) | 11 (12.0) | 8 (8.7) | |
Yes | 29 (31.5) | 26 (28.3) | 0 (0.0) | 3 (3.3) | |